Effect of Advanced Hybrid Closed Loop System, MiniMed 780G in Newly Diagnosed Children and Adolescents With Type 1 Diabetes on Glycemic Control and Patient Reported Outcomes Compared to Standard Insulin Therapy Historical Data (AHCL in New Onset T1D Children Study)

Exclusion Criteria

• •Type 2 diabetes mellitus or MODY diabetes
• •Any untreated comorbidities of type 1 diabetes
• •Medication affecting metabolic control or interfering in the interpretation of HbA1c
• •Pregnancy
• •Untreated diabetes retinopathy, or other causes that in the investigator's opinion, precludes the individual from participating in the trial.
• •Known or suspected allergy to insulin.
• •Regular use of acetaminophen.
• •Lack of reliable telephone facility for contact.
• •Living alone.
• •Severe visual or hearing impairment.
• •Medically documented allergy to the adhesive of plasters or unable to tolerate tape adhesive around sensor placement.
• •Serious skin lesions at areas of the body used for insertion of the glucose sensor.
• •Illicit drugs abuse.
• •Alcohol abuse.
• •Sickle cell disease, haemoglobinopathy, receiving red blood cell transfusion or erythropoietin within 3 months prior to time of enrollment.
• •Eating disorder including anorexia/bulimia.
• •Milk protein allergy.